Anti-p53 [Pab DO-7]
Invented by David Lane from Karolinska Institutet
Invented at University of Dundee
- Datasheet
- References (18)
- Inventor Info
Info
| Catalogue Number | 151293 |
| Applications | ELISA FACS IHC IF WB |
| Antigen/Gene or Protein Targets | p53 (N terminus) |
| Reactivity | Human |
| Relevance |
Anti p53 monoclonal antibody used to analyse and detect ‘the most mutated gene in cancer’ p53, enabling identification of transformed cell lines. Background and Research Application Anti-p53 binds p53 protein, a crucial tumour suppressor protein implicated in over 50% of cancers. p53 is a stress-regulated transcription factor that regulates cell cycle arrest and was first identified as an SV40 large T antigen-binding protein. p53 is involved in many mechanisms of anti-cancer function, and plays a role in apoptosis, genomic stability, cell cycle regulation and inhibition of angiogenesis. p53 is known as the guardian of the genome as it functions to prevent gene mutation. Mutants of p53 which frequently occur in human cancers fail to recognise their DNA binding site, leading to the loss of tumour suppressor activity. p53 is typically found in low levels in healthy cells due to its short half-life, however in disease states it is expressed in high amounts due to somatic mutations and believed to contribute to transformation and malignancy. p53 mutations are found in over 50% of cancers with germline mutations, offering a predisposition to inherited cancer susceptibility syndrome. Understanding the functions of mutant p53 can help in the development of new therapeutic approaches that may be useful in a broad range of cancer types. This antibody was created in by David Lane, who also discovered p53, to measure p53 in various analyses of different tissue samples. |
| Host | Mouse |
| Immunogen UniProt ID | P04637 |
| Positive Control | MDA-MB-231 cell line |
| Subclass | IgG2b |
| Molecular Weight (kDa) | 53 |
| Recommended Growing Conditions | DMEM + 5% FCS |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest Immunocytochemistry (ICC) 1:20-1:200 Flow Cytometry (FACS) Assay Dependent Immunofluorescence (IF) 1:20-1:200 Immunohistochemistry (Paraffin) (IHC (P)) 1:100 - 200 Immunoprecipitation (IP) 1:50-1:100 Western Blot (WB) 1:50-1:200 Anti-p53 reacts very strongly with p53 in conventionally fixed and processed histological sections. It allows for analysis of p53 expression in human tumours, including IHC on paraffin-embedded specimens. Anti-p53 antibody can be used on frozen sections as well as methacarn or formol saline fixed paraffin sections. Concentration 1mg/ml as standard Difference Between Clones All clones were created at the same time as anti-p53 DO-7, and all bind to p53 protein, confirmed via immunoblotting, immunoprecipitation and immunocytochemistry. DO1 secreted large amounts of an IgG2a antibody whilst DO2 and DO7 secreted large amounts of an IgG2b antibody. It is likely DO-2 recognises a denatured epitope. |
| Research Area | Apoptosis and Programmed Cell Death, Cancer, Cell Cycle, DNA Damage and Repair, Epigenetics & Nuclear Signalling |
References: 18 entries
Grass et al. 2019. Leuk Lymphoma. 60(4):886-893. PMID: 30457458.
Kanda et al. 2018. BMC Cancer. 18(1):657. PMID: 29907137.
Murnyák et al. 2017. Oncotarget. 8(28):46348-46362. PMID: 28654422.
Gavressea et al. 2017. Anticancer Res. 37(6):2947-2957. PMID: 28551632.
IHC
The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.
Europe PMC ID: 28551632
İlhan et al. 2016. J Vet Diagn Invest. :. PMID: 27016721.
Expression of p53 protein, Jaagsiekte sheep retrovirus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosis.
Europe PMC ID: 27016721
Alsafadi et al. 2016. Oncotarget. 7(11):12331-43. PMID: 26575022.
Tajima et al. 2015. Pathol Int. :. PMID: 25855894.
A signet-ring cell melanoma arising from a medium-sized congenital melanocytic nevus in an adult: A case report and literature review.
Europe PMC ID: 25855894
Ko et al. 2012. Pathol Int. 62(1):43-8. PMID: 22192803.
Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation.
Europe PMC ID: 22192803
Molenaar et al. 2009. Proc Natl Acad Sci U S A. 106(31):12968-73. PMID: 19525400.
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
Europe PMC ID: 19525400
Stephen et al. 1995. J Mol Biol. 248(1):58-78. PMID: 7537340.
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions.
Europe PMC ID: 7537340
Vojtĕsek et al. 1992. J Immunol Methods. 151(1-2):237-44. PMID: 1378473.
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.
Europe PMC ID: 1378473
Add a reference
References: 18 entries
Grass et al. 2019. Leuk Lymphoma. 60(4):886-893. PMID: 30457458.
Kanda et al. 2018. BMC Cancer. 18(1):657. PMID: 29907137.
Murnyák et al. 2017. Oncotarget. 8(28):46348-46362. PMID: 28654422.
Gavressea et al. 2017. Anticancer Res. 37(6):2947-2957. PMID: 28551632.
IHC
The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.
İlhan et al. 2016. J Vet Diagn Invest. :. PMID: 27016721.
Expression of p53 protein, Jaagsiekte sheep retrovirus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosis.
Alsafadi et al. 2016. Oncotarget. 7(11):12331-43. PMID: 26575022.
Tajima et al. 2015. Pathol Int. :. PMID: 25855894.
A signet-ring cell melanoma arising from a medium-sized congenital melanocytic nevus in an adult: A case report and literature review.
Ko et al. 2012. Pathol Int. 62(1):43-8. PMID: 22192803.
Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation.
Molenaar et al. 2009. Proc Natl Acad Sci U S A. 106(31):12968-73. PMID: 19525400.
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
Stephen et al. 1995. J Mol Biol. 248(1):58-78. PMID: 7537340.
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions.
Vojtĕsek et al. 1992. J Immunol Methods. 151(1-2):237-44. PMID: 1378473.
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.
Add a reference
